Literature DB >> 24025038

The impact of next generation sequencing on the analysis of breast cancer susceptibility: a role for extremely rare genetic variation?

F S M Hilbers1, M P G Vreeswijk, C J van Asperen, P Devilee.   

Abstract

Women with a family history of breast cancer have an approximately twofold elevated risk of the disease. Even though an array of genes has been associated with breast cancer risk the past two decades, variants within these genes jointly explain at most 40% of this familial risk. Many explanations for this 'missing heritability' have been proposed, including the existence of many very rare variants, interactions between genetic and environmental factors and structural genetic variation. In this review, we discuss how next generation sequencing will teach us more about the genetic architecture of breast cancer, with a specific focus on very rare genetic variants. While such variants potentially explain a substantial proportion of familial breast cancer, assessing the breast cancer risks conferred by them remains challenging, even if this risk is relatively high. To assess more moderate risks, epidemiological approaches will require very large patient cohorts to be genotyped for the variant, only achievable through international collaboration. How well we will be able to eventually resolve the missing heritability for breast cancer in a clinically meaningful way crucially depends on the underlying complexity of the genetic architecture.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  breast cancer; familial risk; genetics; sequencing technology

Mesh:

Substances:

Year:  2013        PMID: 24025038     DOI: 10.1111/cge.12256

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  14 in total

Review 1.  Population genetic testing for cancer susceptibility: founder mutations to genomes.

Authors:  William D Foulkes; Bartha Maria Knoppers; Clare Turnbull
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

2.  Prevalence of disease-causing genes in Japanese patients with BRCA1/2-wildtype hereditary breast and ovarian cancer syndrome.

Authors:  Tomoko Kaneyasu; Seiichi Mori; Hideko Yamauchi; Shozo Ohsumi; Shinji Ohno; Daisuke Aoki; Shinichi Baba; Junko Kawano; Yoshio Miki; Naomichi Matsumoto; Masao Nagasaki; Reiko Yoshida; Sadako Akashi-Tanaka; Takuji Iwase; Dai Kitagawa; Kenta Masuda; Akira Hirasawa; Masami Arai; Junko Takei; Yoshimi Ide; Osamu Gotoh; Noriko Yaguchi; Mitsuyo Nishi; Keika Kaneko; Yumi Matsuyama; Megumi Okawa; Misato Suzuki; Aya Nezu; Shiro Yokoyama; Sayuri Amino; Mayuko Inuzuka; Tetsuo Noda; Seigo Nakamura
Journal:  NPJ Breast Cancer       Date:  2020-06-12

Review 3.  Next-generation sequencing for inherited breast cancer risk: counseling through the complexity.

Authors:  Irene R Rainville; Huma Q Rana
Journal:  Curr Oncol Rep       Date:  2014-03       Impact factor: 5.075

4.  Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population.

Authors:  Frédéric Ancot; Suzanna L Arcand; Anne-Marie Mes-Masson; Diane M Provencher; Patricia N Tonin
Journal:  Oncol Lett       Date:  2015-04-20       Impact factor: 2.967

5.  Lynch Syndrome Limbo: Patient Understanding of Variants of Uncertain Significance.

Authors:  Ilana Solomon; Elizabeth Harrington; Gillian Hooker; Lori Erby; Jennifer Axilbund; Heather Hampel; Kara Semotiuk; Amie Blanco; William M P Klein; Francis Giardiello; Lori Leonard
Journal:  J Genet Couns       Date:  2017-01-26       Impact factor: 2.537

6.  Testing for Hereditary Breast Cancer: Panel or Targeted Testing? Experience from a Clinical Cancer Genetics Practice.

Authors:  Jennifer Doherty; Danielle C Bonadies; Ellen T Matloff
Journal:  J Genet Couns       Date:  2014-12-05       Impact factor: 2.537

7.  Genetic Counselors' Experiences Regarding Communication of Reproductive Risks with Autosomal Recessive Conditions found on Cancer Panels.

Authors:  Sarah Mets; Rebecca Tryon; Patricia McCarthy Veach; Heather A Zierhut
Journal:  J Genet Couns       Date:  2015-10-10       Impact factor: 2.537

8.  Next-Generation Testing for Cancer Risk: Perceptions, Experiences, and Needs Among Early Adopters in Community Healthcare Settings.

Authors:  Kathleen R Blazer; Bita Nehoray; Ilana Solomon; Mariana Niell-Swiller; Julie O Culver; Gwen C Uman; Jeffrey N Weitzel
Journal:  Genet Test Mol Biomarkers       Date:  2015-11-05

9.  Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility.

Authors:  Angela R Bradbury; Linda Patrick-Miller; Jessica Long; Jacquelyn Powers; Jill Stopfer; Andrea Forman; Christina Rybak; Kristin Mattie; Amanda Brandt; Rachelle Chambers; Wendy K Chung; Jane Churpek; Mary B Daly; Laura Digiovanni; Dana Farengo-Clark; Dominique Fetzer; Pamela Ganschow; Generosa Grana; Cassandra Gulden; Michael Hall; Lynne Kohler; Kara Maxwell; Shana Merrill; Susan Montgomery; Rebecca Mueller; Sarah Nielsen; Olufunmilayo Olopade; Kimberly Rainey; Christina Seelaus; Katherine L Nathanson; Susan M Domchek
Journal:  Genet Med       Date:  2014-10-09       Impact factor: 8.822

Review 10.  Hereditary ovarian cancer: not only BRCA 1 and 2 genes.

Authors:  Angela Toss; Chiara Tomasello; Elisabetta Razzaboni; Giannina Contu; Giovanni Grandi; Angelo Cagnacci; Russell J Schilder; Laura Cortesi
Journal:  Biomed Res Int       Date:  2015-05-17       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.